ELI LILLY & Co is 50.7x more valuable than Royalty Pharma plc by market capitalization ($1.072 T vs $21.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RPRX | LLY |
|---|---|---|
| Market cap | $21.16 B | $1.072 T |
| US-listed rank | #600 | #10 |
| Revenue (latest FY) | $2.38B | $65.18B |
| Net income (latest FY) | $770.95M | $20.64B |
| Net margin | 32.4% | 31.7% |
| P/E (trailing FY) | 27.4 | 51.9 |
| SEC filings | 588 | 989 |
ELI LILLY & Co is 50.7x more valuable than Royalty Pharma plc by market capitalization ($1.072 T vs $21.16 B).
In their latest fiscal years, Royalty Pharma plc reported $2.38B in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Royalty Pharma plc and ELI LILLY & Co, or browse the full rankings.